Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
TNF inhibitor
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
Related Questions
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Do you continue TNF inhibitors in patients with a new diagnosis of CLL?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
